

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
WO 03/014702 A2

- (51) International Patent Classification<sup>7</sup>: G01N
- (21) International Application Number: PCT/US02/25068
- (22) International Filing Date: 6 August 2002 (06.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/311,027 8 August 2001 (08.08.2001) US
- (71) Applicant: SCHERING CORPORATION [US/US];  
Patent Department - K-6-1 1990, 2000 Galloping Hill  
Road, Kenilworth, NJ 07033-0530 (US).
- (72) Inventors: BAZAN, J., Fernando; 426 Waverley Street,  
#6, Palo Alto, CA 94301 (US). BEEBE, Amy, M.; 348 Fil-  
bert Street, Half Moon Bay, CA 94019 (US). DE WAAL  
MALEFYT, Rene; 891 Muender Avenue, Sunnyvale, CA  
94086 (US). GORMAN, Daniel, M.; 6371 Central Av-  
enue, Newark, CA 94560 (US). KIRK, Peter; 395 E. Eve-  
lyn Avenue, Apt. 137, Sunnyvale, CA 94086 (US). KU-  
RATA, Hirokazu; 1091 Tanland Drive, #212, Palo Alto,  
CA 94303 (US). RENNICK, Donna; 740 Vista Grande,  
Los Altos, CA 94024 (US).
- (74) Agent: FONTENOT, J., Darrell; Schering-Plough Cor-  
poration, Patent Department - K-6-1 1990, 2000 Galloping  
Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS

```

HEMAE80_Hu      MRTPGPLPVLLLLL---LAGAPAARPTPPTCYSRMRALSQEITRDFNLLQVSEPEPCVR
HEMAE80_M        -MSPKTLPLLLLLLVVVVIAWPLAVQSAPPTCYSRMLTLSREIMADFQSLQASEPEDSCVR
                :* .**:* **      :* . * . . :***** :**:* ** :* .**.* :**
HEMAE80_Hu      YLPRLYLDIHNYCVLDKLRDFVASPPCWKVAQVDSLKDKARKLYTIMNSFCRRDLVFLLD
HEMAE80_M        YLPRLYLDIHNYCVLAKLRDFVASPPCWKMAEVDTLKDRVRKLYTIMNSFCRRDLVFLSD
                ***** **:***:***:* .*****
HEMAE80_Hu      DCNALEYPIPVTVLPDRQR
HEMAE80_M        DCSALEDPIPEATGPPDWQS

```

(57) Abstract: Provided are methods of treatment for bone disorders related to bone deposition and resorption dysfunction. These bone disorders may be the result of inflammation, cancers, etc. Provided are methods of using agonists or antagonists of a cytokine molecule.



WO 03/014702 A2

## USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS

5

## FIELD OF THE INVENTION

The present invention relates generally to uses of mammalian cytokine-like molecules and related reagents. More specifically, the invention relates to identification of mammalian cytokine-like proteins and inhibitors thereof that affect medical conditions such as bone and inflammatory disorders.

## BACKGROUND OF THE INVENTION

The skeletal system, at first glance, appears to be a rigidly fixed and unchanging entity. However, this system is actually the result of a dynamic process involving a carefully regulated equilibrium between bone matrix deposition and resorption. These opposing actions are mediated through various bone associated cells including osteoblasts and osteoclasts, respectively.

Osteoblasts, the primary type of bone forming cell, are located on the surface of bone. These cells synthesize, transport and arrange many bone matrix proteins. Osteoblasts express several cell surface receptors including those for hormones (e.g., parathyroid hormone, Vitamin D, and estrogen), cytokines, and growth factors. (See, Cotrone, et al. (eds.) (1994) Robbins: Pathologic Basis of Disease, W.B. Saunders Company, Philadelphia, PA.)

Osteoclasts are the cells responsible for bone resorption. These multinucleated granulocyte-monocyte lineage derived cells are also located on the surface of the bone. Osteoclasts are responsible for the release of a multitude of enzymes that act on disassembly of the matrix proteins into amino acids. The osteoclast released enzymes also activate certain growth factors and other enzymes, such as collagenase.

The opposing actions of osteoblasts and osteoclasts must be kept in balance to maintain skeletal integrity and calcium metabolism. The most common problem associated with dysregulation of this balance occurs when the rate of resorption exceeds the rate of

deposition. This results in a loss of bone mass, e.g., as seen in osteoporosis, inflammatory conditions such as rheumatoid arthritis, and many cancers. (See, e.g., Rodan and Martin, (2000) Science 289:1508-1514.)

Some molecular mechanisms of osteoclast regulation have recently been discovered. One such molecule, RANKL, has been implicated in enhanced osteoclast function. (See, e.g., Suda et al. (1999) Endocr. Rev. 20:345-357.) RANKL, a TNF family member, is normally expressed on osteoblasts and activated T cells, binds to RANK which is expressed on osteoclasts and dendritic cells. (See, e.g., Wong, et al. (1999) J. Leuk. Biol. 65:715-724). When RANK is activated via binding to RANKL, a cascade of signaling molecules are activated resulting in the maturation of osteoclasts and enhancement of their bone resorption functions.

The balance of bone resorption and deposition will most likely involve a complex network of several regulatory molecules. As yet, many of these molecules and their functions have not been elucidated. The present invention satisfies this need.

#### BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows a sequence alignment between human HEMAE80 polypeptide (SEQ ID NO:2) and mouse HEMAE80 polypeptide (SEQ ID NO:4).

#### SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of the role of a cytokine-like molecule, HEMAE80, in bone deposition and resorption.

The present invention provides methods of modulating bone resorption by contacting a cell with an agonist of HEMAE80; an antagonist of HEMAE80. HEMAE80 further comprises a polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:4. In another embodiment, the antagonist of HEMAE80 is an antibody or binding fragment thereof. The antibody is a polyclonal antibody; or a monoclonal antibody.

The present invention also provides for a method of treating a bone resorption disorder comprising administering an antagonist of HEMAE80. In another embodiment, HEMAE80 is administered in combination with another therapeutic. In yet another embodiment, the antagonist is an antibody which specifically binds HEMAE80 and prevents loss of bone mineral density. The disorders embodied are: osteoporosis; osteopetrosis;

Paget's disease; osteodystrophy; a result of a hemopoietic stem/progenitor cell (HSPC) hyperplasia; a result of an immune disorder; or a result of a cancer.

The present invention further embodies a method of treating a bone deposition disorder comprising administering an agonist of HEMA E80. The agonist inhibits bone  
5 deposition and is used to treat: excessive ossification of skeletal bone; ossification of cartilage; or Van Buchem's disease.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

## I. General

The characteristic of the skeletal system is a dynamic entity whose health is predicated on a delicate equilibrium between bone deposition and bone resorption. Osteoblasts and osteoclasts are the key cell types responsible for this regulatory processes

The present invention resulted from studies on a secreted cytokine molecule, HEMAE80. HEMAE80 appears to be expressed by CD34+ hematopoietic stem/progenitor cells (HSPCs; see, e.g., Liu, et al. (2000) Genomics 65:283-292), cartilage, chondrocytes, endothelial cells, and osteoblasts. Quantitative PCR in human and mouse cells and tissues showed high levels of expression in mouse aorta and ears (skin/cartilage tissue). In the human, high expression was found in fetal spleen, fetal gall bladder, CD14+ ex vivo derived dendritic cells, and macrophages.

HSPCs reside in the bone marrow, in contact with bone marrow stromal cells. Stromal cells of the bone marrow are of the same lineage as osteoblasts and there is evidence for phenotype plasticity allowing interconversion of the stromal cells and osteoblasts (see, e.g., Krebsbach, et al. (1999) Crit. Rev. Oral Biol. Med. 10:165-181). Therefore, HSPCs may secrete a factor that affects osteoblast development. This is evidenced by the fact that hyperplasia of HSPCs can lead to osteoporosis (see, e.g., Ascenzi (1976) The Biochemistry and Physiology of Bone, G. Bourne (ed.) Academic Press, New York, NY; and Tunaci, et al. (1999) Eur. Radiol. 9:1804-1809). Further, during skeletal development, invasion of nascent bone by HSPCs is required to prevent excessive ossification (see, e.g., Tavassoli and Yoffey (eds.)(1983) Bone Marrow: Structure and Function, Academic Press, New York, NY; Gotoh, et al. (1995) Calcif. Tissue Int. 56:246-251; and Gundle et al. (1995) Bone 16:597-601).

Chondrocytes are the main cell type of cartilage, and are also of the bone marrow/osteoblast lineage. In order to prevent ossification of cartilage tissue, osteoblast activity must be inhibited to prevent entry into cartilage tissue. In view of their shared lineage, chondrocytes are also a potential target of HEMAE80.

Adenovirus delivery of HEMAE80 protein to mice resulted in significantly less bone mineral density in treated vs. untreated animals. Neonatal mice treated with purified human HEMAE80 protein had lower bone mineral density than mice receiving control treatment.

Administration of purified human HEMA E80 protein to adult mice led to a 10% reduction in bone mineral density compared to pre-treatment levels, and significantly reduced limb bone length compared to control-treated animals. Finally both adenoviral and protein delivery of HEMA E80 to SCID mice implanted with human bone resulted in differences in comparison with normal bone. In particular, HEMA E80 treated bone had reduced marrow cellularity, uniform acellular deposits, and cell adhering to bone spines. Taken together, HEMA E80 can be a target for modulation of bone resorption and deposition.

Structurally, human HEMA E80 polynucleotide (SEQ ID NO:1) encodes a polypeptide (SEQ ID NO:2), a member of the hematopoietic cytokine family, is characterized by the presence of 4  $\alpha$ -helix bundle structures. Similarly, mouse HEMA E80 polynucleotide (SEQ ID NO:3) encodes a polypeptide (SEQ ID NO:4). Figure 1 shows a sequence alignment between human HEMA E80 polypeptide (SEQ ID NO:2) and mouse HEMA E80 polypeptide (SEQ ID NO:4).

Secretion of HEMA E80 from CD34+ hematopoietic progenitor cells suggests that this molecule may have additional activities on the differentiation and proliferation of immune cells. HEMA E80 was mapped to human chromosome 4 in a region known for recurrent chromosomal translocations [t(4;14)(p16.3; q32)] in Multiple Myeloma. This suggests that HEMA E80 may be the target of this abnormality and may contribute to its tumorigenesis.

20

## II. Antagonists and agonists

Blockage of the activities of HEMA E80 can be achieved by antagonists of the cytokine, e.g., antibodies to the ligand, antibodies to the receptor, etc. Interference with the ligand-receptor interaction has proven to be an effective strategy for the development of antagonists.

25

There are various means to antagonize the activity mediated by ligand. Two apparent means are to block the ligand with antibodies; a second is to block the receptor with antibodies. Various epitopes will exist on each which will block their interaction, e.g., causing steric hindrance blocking interaction. The correlation of ability to block signaling would not necessarily be expected to correlate with binding affinity to either ligand or receptors. Another means is to use a ligand mutein which retains receptor binding activity,

30

but fails to induce receptor signaling. The mutein may be a competitive inhibitor of signaling ligand.

Alternatively, small molecule libraries may be screened for compounds which may block the interaction or signaling mediated by an identified ligand-receptor pairing.

5 The present invention provides for the use of an antibody or binding composition which specifically binds to a specified cytokine ligand, preferably mammalian, e.g., primate, human, cat, dog, rat, or mouse. Antibodies can be raised to various cytokine proteins, including individual, polymorphic, allelic, strain, or species variants, and fragments thereof, both in their naturally occurring (full-length) forms or in their recombinant forms.

10 Additionally, antibodies can be raised to receptor proteins in both their native (or active) forms or in their inactive, e.g., denatured, forms. Anti-idiotypic antibodies may also be used.

A number of immunogens may be selected to produce antibodies specifically reactive with ligand or receptor proteins. Recombinant protein is a preferred immunogen  
15 for the production of monoclonal or polyclonal antibodies. Naturally occurring protein, from appropriate sources, e.g., primate, rodent, etc., may also be used either in pure or impure form. Synthetic peptides, made using the appropriate protein sequences, may also be used as an immunogen for the production of antibodies. Recombinant protein can be expressed and purified in eukaryotic or prokaryotic cells as described, e.g., in Coligan, et al.  
20 (eds. 1995 and periodic supplements) Current Protocols in Protein Science John Wiley & Sons, New York, NY; and Ausubel, et al (eds. 1987 and periodic supplements) Current Protocols in Molecular Biology, Greene/Wiley, New York, NY. Naturally folded or denatured material can be used, as appropriate, for producing antibodies. Either monoclonal or polyclonal antibodies may be generated, e.g., for subsequent use in immunoassays to  
25 measure the protein, or for immunopurification methods.

Methods of producing polyclonal antibodies are well known to those of skill in the art. Typically, an immunogen, preferably a purified protein, is mixed with an adjuvant and animals are immunized with the mixture. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the  
30 protein of interest. For example, when appropriately high titers of antibody to the immunogen are obtained, usually after repeated immunizations, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for

antibodies reactive to the protein can be performed if desired. See, e.g., Harlow and Lane; or Coligan. Immunization can also be performed through other methods, e.g., DNA vector immunization. See, e.g., Wang, et al. (1997) Virology 228:278-284.

5 Monoclonal antibodies may be obtained by various techniques familiar to  
researchers skilled in the art. Typically, spleen cells from an animal immunized with a  
desired antigen are immortalized, commonly by fusion with a myeloma cell. See, Kohler  
and Milstein (1976) Eur. J. Immunol. 6:511-519. Alternative methods of immortalization  
include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other  
10 methods known in the art. See, e.g., Doyle, et al. (eds. 1994 and periodic supplements) Cell  
and Tissue Culture: Laboratory Procedures, John Wiley and Sons, New York, NY.  
Colonies arising from single immortalized cells are screened for production of antibodies of  
the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies  
produced by such cells may be enhanced by various techniques, including injection into the  
peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which  
15 encode a monoclonal antibody or a binding fragment thereof by screening a DNA library  
from human B cells according, e.g., to the general protocol outlined by Huse, et al. (1989)  
Science 246:1275-1281.

Antibodies or binding compositions, including binding fragments and single chain  
versions, against predetermined fragments of ligand or receptor proteins can be raised by  
20 immunization of animals with conjugates of the fragments with carrier proteins.  
Monoclonal antibodies are prepared from cells secreting the desired antibody. These  
antibodies can be screened for binding to normal or defective protein. These monoclonal  
antibodies will usually bind with at least a  $K_D$  of about 1 mM, more usually at least about  
300  $\mu$ M, typically at least about 10  $\mu$ M, more typically at least about 30  $\mu$ M, preferably at  
25 least about 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

In some instances, it is desirable to prepare monoclonal antibodies (mAbs) from  
various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of  
techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al.  
(eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, CA,  
30 and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual  
CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.)



Academic Press, New York, NY; and particularly in Kohler and Milstein (1975) Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Summarized briefly, this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.

Other suitable techniques involve selection of libraries of antibodies in phage or similar vectors. See, e.g., Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies.

Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.

Patents teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see, Cabilly, U.S. Patent No. 4,816,567; and Queen, et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033; or made in transgenic mice, see Mendez, et al. (1997) Nature Genetics 15:146-156; also see Abgenix and Medarex technologies.

Antibodies are merely one form of specific binding compositions. Other binding compositions, which will often have similar uses, include molecules that bind with specificity to ligand or receptor, e.g., in a binding partner-binding partner fashion, an antibody-antigen interaction, or in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent, e.g., proteins which specifically associate with desired protein. The molecule may be a polymer, or chemical reagent. A functional analog may be a protein with structural modifications, or may be a structurally unrelated molecule,

e.g., which has a molecular shape which interacts with the appropriate binding determinants. Antibody binding compounds, including binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be useful as non-neutralizing binding compounds and can be coupled to toxins or radionuclides so that when the binding  
5 compound binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these binding compounds can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Agonists include the cytokine protein identified (see, e.g., SEQ ID NO:2 and 4). Proteins of those sequences, or variants thereof, will be used to induce receptor signaling.

10

### III. Diagnostic uses; Therapeutic compositions, methods

The invention provides means to address various bone, immune, or cancer related disorders. The etiology and pathogenesis are often not well understood, but they cause significant discomfort or morbidity in patients. As noted above, administration of the  
15 purified or adenovirus produced protein results in loss of bone density in various animal models. Collectively these studies suggest that agonizing or antagonizing this cytokine or its receptor, with the appropriate entity may offer a therapeutic modality in bone, immune, or cancer related disorders.

Diagnostic methods include such aspects as prediction of prognosis; definition of  
20 subsets of patients who will either respond or not respond to a particular therapeutic course; diagnosis of bone or immune related disorders or subtypes of these disorders; or assessing response to therapy. Antagonists or agonists to HEMA80 activity can be implicated in a manner suggesting significant therapeutic effects, e.g., to decrease or prevent occurrence of symptoms. The antagonists and/or agonists of the present invention can be administered  
25 alone or in combination with another inhibitor or agonist of the same or accompanying pathway; or other compounds used for the treatment of symptoms, e.g., antagonists, or steroids such as glucocorticoids.

Certain antagonists or agonists may be useful to slow down the process of bone  
30 density loss or ossification. Prevention of bone loss in disorders including but not limited to, osteoporosis, osteodystrophy, osteopetrosis, bone loss as a result of immune or cancer related disorders, or Paget's disease, would be advantageous. Enhanced bone resorption

would be similarly be advantageous in disorders including, but not limited to, skeletal ossification, cartilage ossification, and Van Buchem's disease.

This may be effected by either direct administration of the agonist or antagonist, or perhaps using a gene therapy strategy. Antagonism may be effected, e.g., by antisense  
5 treatment, antibodies, or other suppression of HEMA80 effects.

To prepare pharmaceutical or sterile compositions including the antibody, binding composition thereof, cytokine agonist, or small molecule antagonist, the entity is admixed with a pharmaceutically acceptable carrier or excipient which is preferably inert. Preparation of such pharmaceutical compositions is known in the art, see, e.g., Remington's  
10 Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984).

Antibodies, binding compositions, or cytokines are normally administered parentally, preferably intravenously. Since such proteins or peptides may be immunogenic they are preferably administered slowly, either by a conventional IV administration set or  
15 from a subcutaneous depot, e.g. as taught by Tomasi, et al, U.S. patent 4,732,863. Means to minimize immunological reactions may be applied. Small molecule entities may be orally active.

When administered parenterally the biologics will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically  
20 acceptable parenteral vehicle. Such vehicles are typically inherently nontoxic and nontherapeutic. The therapeutic may be administered in aqueous vehicles such as water, saline, or buffered vehicles with or without various additives and/or diluting agents. Alternatively, a suspension, such as a zinc suspension, can be prepared to include the peptide. Such a suspension can be useful for subcutaneous (SQ) or intramuscular (IM)  
25 injection. The proportion of biologic and additive can be varied over a broad range so long as both are present in effective amounts. The antibody is preferably formulated in purified form substantially free of aggregates, other proteins, endotoxins, and the like, at concentrations of about 5 to 30 mg/ml, preferably 10 to 20 mg/ml. Preferably, the endotoxin levels are less than 2.5 EU/ml. See, e.g., Avis, et al. (eds.)(1993) Pharmaceutical  
30 Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets 2d ed., Dekker, NY; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY; Fodor, et al. (1991) Science

251:767-773, Coligan (ed.) Current Protocols in Immunology; Hood, et al. Immunology Benjamin/Cummings; Paul (ed.) Fundamental Immunology; Academic Press; Parce, et al. (1989) Science 246:243-247; Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011; and Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995

Selecting an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells, timing of administration, etc. Preferably, an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects. Accordingly, the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate antibody doses is found in, e.g. Bach et al., chapter 22, in Ferrone, et al. (eds. 1985) Handbook of Monoclonal Antibodies Nokes Publications, Park Ridge, NJ; and Haber, et al. (eds.) (1977) Antibodies in Human Diagnosis and Therapy, Raven Press, New York, NY (Russell, pgs. 303-357, and Smith, et al., pgs. 365-389). Alternatively, doses of cytokine or small molecules are determined using standard methodologies.

Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects. Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced. Preferably, a biologic that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing a humoral response to the reagent.

The total weekly dose ranges for antibodies or fragments thereof, which specifically bind to ligand or receptor range generally from about 10  $\mu\text{g}$ , more generally from about 100  $\mu\text{g}$ , typically from about 500  $\mu\text{g}$ , more typically from about 1000  $\mu\text{g}$ , preferably from about 5 mg, and more preferably from about 10 mg per kilogram body weight. Generally the range will be less than 100 mg, preferably less than about 50 mg, and more preferably less than about 25 mg per kilogram body weight. Agonist or small molecule therapeutics may be used at similar molarities.

The weekly dose ranges for antagonists of cytokine receptor mediated signaling, e.g., antibody or binding fragments, range from about 1  $\mu\text{g}$ , preferably at least about 5  $\mu\text{g}$ , and more preferably at least about 10  $\mu\text{g}$  per kilogram of body weight. Generally, the range will be less than about 1000  $\mu\text{g}$ , preferably less than about 500  $\mu\text{g}$ , and more preferably less than about 100  $\mu\text{g}$  per kilogram of body weight. Dosages are on a schedule which effects the desired treatment and can be periodic over shorter or longer term. In general, ranges will be from at least about 10  $\mu\text{g}$  to about 50 mg, preferably about 100  $\mu\text{g}$  to about 10 mg per kilogram body weight. Cytokine agonists or small molecule therapeutics will typically be used at similar molar amounts, but because they likely have smaller molecular weights, will have lesser weight doses.

The present invention also provides for administration of biologics in combination with known therapies, e.g., steroids, particularly glucocorticoids, which alleviate the symptoms, e.g., associated with inflammation, or antibiotics or anti-infectives. Daily dosages for glucocorticoids will range from at least about 1 mg, generally at least about 2 mg, and preferably at least about 5 mg per day. Generally, the dosage will be less than about 100 mg, typically less than about 50 mg, preferably less than about 20 mg, and more preferably at least about 10 mg per day. In general, the ranges will be from at least about 1 mg to about 100 mg, preferably from about 2 mg to 50 mg per day. Suitable dose combinations with antibiotics, anti-infectives, or anti-inflammatories are also known.

The phrase "effective amount" means an amount sufficient to ameliorate a symptom or sign of the medical condition. Typical mammalian hosts will include mice, rats, cats, dogs, and primates, including humans. An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side affects. When in combination, an effective amount is in ratio to a combination of components and the effect is not limited to individual components alone

An effective amount of therapeutic will decrease the symptoms typically by at least about 10%; usually by at least about 20%; preferably at least about 30%; or more preferably at least about 50%. The present invention provides reagents which will find use in therapeutic applications as described elsewhere herein, e.g., in the general description for treating disorders associated with the indications described above. Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. Harrison's

Principles of Internal Medicine, McGraw-Hill, NY; Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn; Langer (1990) Science 249:1527-1533; Merck Index, Merck & Co., Rahway, New Jersey; and Physician's Desk Reference (PDR); Cotran, et al. (eds), supra; and Dale and Federman (eds.) (2000) Scientific American Medicine, Healthon/WebMD, New York, NY.

The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the inventions to the specific embodiments.

10

## EXAMPLES

### I. General Methods

Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual, (2d ed.), vols. 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology, Greene/Wiley, New York. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Meth. Enzymol., vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QIAGEN, Inc., Chatsworth, CA.

Computer sequence analysis is performed, e.g., using available software programs, including those from the GCG (U. Wisconsin) and GenBank sources. Public sequence databases were also used, e.g., from GenBank and others.

## 5 II. IDENTIFICATION OF HEMAE80

The human HEMAE80 clone was identified in the HGS (Rockville, MD) database as a candidate secreted protein using the PSORT and SignalP leader prediction algorithms. HGS clone HEMAE80 in PC5 mammalian expression vector was prepared and sequence verified. 293T-cells were transiently transfected and newly synthesized proteins were  
10 metabolically labeled using [<sup>35</sup>S] methionine. The transfection supernatant was analyzed on SDS PAGE. HEMAE80 transfected cells secrete a protein of 15 kD by IVR.

The mouse HEMAE80 clone was encoded by two public ESTs (BB568033, BF449650, dbEST), identified by BLAST using the coding region of human HEMAE80. The mouse ESTs were used to design oligonucleotide primers allowing amplification of the  
15 coding region of the gene by nested PCR, using Mouse 17-day embryo Marathon-ready cDNA (Clontech) as template. Incorporation of HindIII and NotI restriction sites into the cloning oligonucleotides allowed cloning into the adenoviral expression vectors.

## 20 III. PRODUCTION OF HEMAE80 PROTEIN

To generate an adenovirus transfer vector, the HEMAE80 clone was digested with NotI and XbaI and cloned into QBI AdCMV5-GFP-M#1 in the NotI and XbaI site. The vector and recombinant adenovirus production were as described in Hoek, R. et al, (2000) Science 290:1768-1771. Mammalian HEK293 cells were infected with this recombinant  
25 adenovirus and the supernatant was subjected to purification by cation exchange, anion exchange, followed by size exclusion chromatography. The protein product was characterized and quantified by SDS PAGE. Estimation of protein purity was ~90%, based upon visualization of the SDS PAGE commassie stained gel. The endotoxin level in the preparation as measured by Limulus Amebocyte Lysate QCL-1000 (BioWhittaker) was 6.7 EU/ml.

#### IV. DISTRIBUTION OF HEMA E80 MESSAGE

RNA was isolated from tissues or cultured cells either using RNA-easy mini kits (Qiagen, Valencia, CA) or RNazol B (Tel-test Inc., Friendswood, TX), according to  
5 manufacturers instructions. 2 µg total RNA was reverse transcribed into cDNA using 500 ng Oligo (dT) 12- 18 (Boehringer), 50 ng p(dN6) (Pharmacia, Peapack, NJ), 0.5 mM dNTP mix (Boehringer), 5 mM DTT and 200 U Superscript II RNA'se H-RT (Gibco BRL) in a 20 µl reaction at 42 °C for 50 min. Alternatively, cDNAs from various libraries were used as templates for quantitative PCR.

10 Twenty to fifty nanograms of cDNA per reaction was used as template for quantitative PCR and analyzed for the expression of human cytokine, cytokine receptor, or transcription factor genes by the fluorogenic 5'-nuclease PCR assay [Holland, 1991 #28] using the GeneAmp 5700 or ABI Prism 7700 Sequence Detection Systems (Perkin-Elmer, Foster City, CA). The amplicons used for human HEMA E 80 covered bp 358 - 405, and  
15 mouse HEMA E 80 xx respectively (numbering starts at start codon), and were analyzed either using a FAM labeled probe or with the intercalating fluorochrome dye SYBR Green. Sequences were as follows:

hHEMAE80 forward : ATGACTGCAATGCCTTGGAAT (SEQ ID NO:5),  
20 hHEMAE80 reverse : TCCCTTAGCGCTGACGATCT (SEQ ID NO:6), and  
hHEMAE80 probe :  
6FAM-CCCAATCCCAGTGACTACGGTCCTGC-TAMRA (SEQ ID NO:7).

Primers and probes detecting human cytokine and cytokine receptor expression were  
25 obtained as pre-developed assay reagents (PDAR's) (Perkin Elmer). PCR reactions were assembled using Taqman Universal PCR Master Mix or SYBR Green PCR master mix (ABI Foster City CA) according to the manufacturer's protocols to yield final concentrations of 1X PCR buffer, 200 µM dATP, dCTP, dGTP and 400 µM dUTP, 5.5 mM MgCl<sub>2</sub>, 1.25 U AMPLITAQ Gold DNA polymerase, Passive Reference I, and 0.5 U AMP-ERASE Uracil-  
30 N-glycosylase. Forward and reverse primers were added at 900 nM each and FAM labelled



probes at 250 nM. The expression of 18S rRNA was measured in a multiplex assay in each sample and served as internal control for amount of input cDNA.

Multiplex assays contained 18S rRNA forward primer, reverse primer and VIC labeled probe at 50 nM in the PCR reaction. Forward and reverse primers were used at 200 nM in (singleplex) SYBR Green assays. The thermal cycling conditions included 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles of amplification at 95°C for 15 s, and 55 °C for 1 min for denaturing and anneal-extension, respectively. Absolute quantitation was based on comparison to standard curves obtained by 10-fold serial dilutions of plasmid DNA containing the gene of interest as insert and corrected for amount of cDNA as determined by expression of the internal control.

#### V. ADENOVIRAL DELIVERY OF HEMA E80 TO C57BL/6J AND NEONATAL MICE

Adenoviral delivery of HEMA E80 to 14 week old C57BL/6J mice was performed as follows. Fourteen week old female C57/BL/6 mice were injected intravenously with  $5 \times 10^{10}$  replication deficient adenovirus expressing mHEMA E80 (SEQ ID NO:4) or control adenovirus expressing GFP. Fourteen days later, tibias were removed and the proximal ends were analyzed for trabecular bone mineral density by peripheral quantitative computed tomography (pQCT). Treated bones had significantly less trabecular bone than the control animals ( $p=0.029$ ) ( $n=3$  treated and 3 control).

Neonatal mice were given 6.5 micogram of human HEMA E80 protein every other day i.p. They received 8 i.p. injections totalling 52 micrograms/mouse. The mice were taken down a day after the last injection of protein and the tibia's placed in 70% ethynol followed by bone density measurements.

#### VI. TREATMENT OF NEONATAL AND ADULT MICE WITH RECOMBINANT HEMA E80 PROTEIN

Neonatal mice received a course of 8 i.p. injections of 6.5 micrograms of recombinant human HEMA E80 protein (or PBS control) on alternate days, totaling 52 micrograms per mouse. The mice were taken down one day after the last injection of protein and the bone mineral density of tibias analyzed by pQCT. Bone mineral density (BMD) was significantly reduced in HEMA E80-treated mice compared to animals receiving control injections ( $p=0.011$ ).

Age- sex- and weight-matched adult Swiss-Webster mice received a course of 10 i.p. injections of 6.5 micrograms of recombinant human HEMAE80 protein (or PBS control) on alternate days (n=8 treated, 8 control). The BMD of the left tibia of each mouse was analyzed by pQCT before and after the course of treatment. Length of left tibia was measured after treatment. The change in BMD was significantly greater in HEMAE80-treated animals than in control animals (p=0.0105), with treated animals showing a mean BMD reduction of 10%. Mean tibia length was significantly shorter in HEMAE80-treated mice than in control mice (p=0.0217). HEMAE80-treatment did not affect body mass.

## VII. HEMAE80 IN SCID MICE

Rag2 x gc <sup>-/-</sup> 129sv mice lack T cells, B cells and NK cells are immunocompromised and can be transplanted with human tissues without adverse effects to constitute scid-hu mice. Human organs that have been successfully transplanted include fetal liver, fetal bone, fetal thymus, PBMC and fetal skin. Since HEMAE80 was found to be abundantly expressed in libraries of tissues containing high amounts of cartilage, rag2 x gc <sup>-/-</sup> mice were transplanted with human fetal bone to test its biological effects.

Human fetal bone pieces (2 per mouse) were transplanted at each flank under the skin and allowed to establish for a period of four weeks. Subsequently, Hema80 was administered to the mice either as purified protein or as adenovirus expressing the HEMAE80 cDNA. Adenovirus expressing GFP (green fluorescent protein) or human HEMAE80 protein was administered iv at 10<sup>10</sup> cfu . At sixteen days after administration, mice were sacrificed, human bones and human bones collected. One bone of each mouse was decalcified and examined by histology. Cells were collected from the colateral bone and the expression of genes involved in hematopoiesis and bone metabolism were analyzed by quantitative "real time" PCR following preparation of cDNA. In addition, hind legs of the mice were dissected and analyzed for bone characteristics including trabecular bone mineral density of the proximal tibia's. Treatment of animals with adeno-HEMAE80 resulted in a trend towards bone loss.

Hematoxylin and Eosin (HE) staining of human bone slides from adenovirus-GFP treated mice showed normal bone morphology with bone marrow containing hematopoietic cells including granulocytes. In contrast, slides from HEMAE80 treated mice showed a strong reduction in the cellularity of the bone marrow and a greater presence of stroma with

probably deposition of connective tissue. In addition, bone fragments were flanked by large connective tissue cells. These results indicate that HEMAE80 has profound effects on bone marrow composition and bone morphology.

Quantitative PCR analyses indicated a 24 fold increase in the levels of Collagen type 10A; a 2.2 fold increase in the levels of collagen 7B; a 4 fold increase in the level of RANKL; a 2.5 fold increase in the levels of IL-6; and a 3 fold decrease in the level of CD14 in the cDNA samples prepared from HEMAE80 treated mice. This was specific since the expression levels of other genes involved in bone remodeling including IL-8, Collagen 1 A2, Collagen 5 A2, Collagen 6 A3, Timp1, IL-7, RANK, IL-1, CD40, gamma-c, GM-CSF, IL-3, IL-15 and TGF- $\beta$  were not affected by more than 2 fold.

HEMAE 80 purified protein was administered ip at concentrations of 10, 2, and 0.4 microgram per mouse per day for 7 days. Mice were sacrificed, human bones collected, and cells harvested 24 hrs following the last administration. The expression of genes involved in hematopoiesis and bone metabolism were analyzed by quantitative "real time" PCR. In addition, hind legs of mice were dissected and analyzed for bone characteristics including trabecular mineral bone density.

Bone density measurements showed a slight decrease in trabecular bone. Quantitative PCR analyses also indicated a greater than 2 fold increase RNAK, RANKL, IL-1, IL-6, CD40, IL-15, and GCSF.

20

All citations herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled; and the invention is not to be limited by the specific embodiments that have been presented herein by way of example.

25

## WHAT IS CLAIMED IS:

1. A method of modulating bone resorption comprising contacting a cell with:
  - a) an agonist of HEMA E80; or
  - 5 b) an antagonist of HEMA E80.
  
2. The method of Claim 1, wherein HEMA E80 comprises a polypeptide sequence of SEQ ID NO:2 or SEQ ID NO:4.
  
- 10 3. The method of Claim 1, wherein the antagonist of HEMA E80 is an antibody or binding fragment thereof.
  
4. The method of Claim 1, wherein the antibody is:
  - a) a polyclonal antibody; or
  - 15 b) a monoclonal antibody;
  
5. A method of treating a bone resorption disorder, said method comprising administering an antagonist of HEMA E80.
  
- 20 6. The method of Claim 5, wherein said administering is in combination with another therapeutic.
  
7. The method of Claim 5, wherein the antagonist is an antibody which specifically binds HEMA E80 and prevents loss of bone mineral density.
  
- 25 8. The method of Claim 5, wherein the bone resorption disorder is:
  - a) osteoporosis;
  - b) osteopetrosis;
  - c) Paget's disease;
  - 30 d) osteodystrophy;
  - e) a result of a hemopoietic stem/progenitor cell (HSPC) hyperplasia;
  - f) a result of an immune disorder; or

g) a result of a cancer.

9. A method of treating a bone deposition disorder, said method comprising administering an agonist of HEMA E80.

5

10. The method of Claim 9, wherein the agonist inhibits bone deposition.

11. The method of Claim 9, wherein the bone deposition disorder is:

a) excessive ossification of skeletal bone;

10

b) ossification of cartilage; or

c) Van Buchem's disease.

HEMAE80\_Hu  
 HEMA80\_M  
 MRTPGPLPVLLLL--LAGAPAAARPTPPPTCYSRMRALSQEITRDFNLLQVSEPEPCVR  
 -MSPKTLPLLLLLVVVVIWPLAVQSAFPTCYSRMLTLSREIMADFQSLQASEPEDSCVR  
 :\* . \*\* : \*\*\*\* \* . \* . : : \*\*\*\* \* : \*\* : \*\* . \*\* . : . \*\* \*

HEMAE80\_Hu  
 HEMA80\_M  
 YLPRLYLDIHNYCVLDKLRDFVASPPCWKVAQVDSLKDKARKLYTIMNSFCRRDLVFLLD  
 YLPRLYLDIHNYCVLAKLRDFVASPQCWKMAEVDTLKDRVRKLYTIMNSFCRRDLVFLSD  
 \*\*\*\*\* \* . \*\* : \*\* : \*\* : \*\* : \*\* : \*\* : \*\* : \*\* : \*\* : \*\* : \*\* \*

HEMAE80\_Hu  
 HEMA80\_M  
 DCNALEYPIPVTTVLPDRQR  
 DCSALEDPIPEATGPPDWQS

FIG. 1

## SEQUENCE LISTING

<110> Bazan, J. Fernando  
 Beebe, Amy M.  
 de Waal Malefyt, Rene  
 Gorman, Daniel M.  
 Kirk, Peter  
 Kurata, Hiro  
 Rennick, Donna

<120> USES OF MAMMLIAN CYTOKINE; RELATED REAGENTS

<130> DX01465P

<160> 7

<170> PatentIn version 3.1

<210> 1

<211> 984

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (12)..(419)

<223>

<400> 1

cgcctggcac c atg agg acg cct ggg cct ctg ccc gtg ctg ctg ctg ctc  
 50

Met Arg Thr Pro Gly Pro Leu Pro Val Leu Leu Leu Leu  
 1 5 10

ctg gcg gga gcc ccc gcc gcg egg ccc act ccc ccg acc tgc tac tcc  
 98

Leu Ala Gly Ala Pro Ala Ala Arg Pro Thr Pro Pro Thr Cys Tyr Ser  
 15 20 25

cgc atg cgg gcc ctg agc cag gag atc acc cgc gac ttc aac ctc ctg  
 146

Arg Met Arg Ala Leu Ser Gln Glu Ile Thr Arg Asp Phe Asn Leu Leu  
 30 35 40 45

cag gtc tcg gag ccc tcg gag cca tgt gtg aga tac ctg ccc agg ctg  
 194

Gln Val Ser Glu Pro Ser Glu Pro Cys Val Arg Tyr Leu Pro Arg Leu  
 50 55 60

tac ctg gac ata cac aat tac tgt gtg ctg gac aag ctg cgg gac ttt  
 242

Tyr Leu Asp Ile His Asn Tyr Cys Val Leu Asp Lys Leu Arg Asp Phe  
 65 70 75

gtg gcc tcg ccc ccg tgt tgg aaa gtg gcc cag gta gat tcc ttg aag  
 290

Val Ala Ser Pro Pro Cys Trp Lys Val Ala Gln Val Asp Ser Leu Lys  
 80 85 90

gac aaa gca cgg aag ctg tac acc atc atg aac tcg ttc tgc agg aga  
 338

Asp Lys Ala Arg Lys Leu Tyr Thr Ile Met Asn Ser Phe Cys Arg Arg  
 95 100 105

gat ttg gta ttc ctg ttg gat gac tgc aat gcc ttg gaa tac cca atc

386

Asp Leu Val Phe Leu Leu Asp Asp Cys Asn Ala Leu Glu Tyr Pro Ile  
 110 115 120 125

cca gtg act acg gtc ctg cca gat cgt cag cgc taaggaact gagaccagag  
 439

Pro Val Thr Thr Val Leu Pro Asp Arg Gln Arg  
 130 135

aaagaacca agagaactaa agttatgtca gctaccaga cttaatgggc cagagccatg  
 499

accctcacag gtcttggtt agttgtatct gaaactgtta tgtatctctc taccttctgg  
 559

aaaacagggc tggattcct accaggaac ctctttgag catagagta gcaacctgac  
 619

ttctcattcc cttgactcat gtcttgccag gatgggttaga tacacagcat gttgatttgg  
 679

tcactaaaaa gaagaaaagg accaacaagc ttcactttta tgaacaacta ttttgagaac  
 739

atgcacaata gtatgttttt attactgggtt taatggagta atggtacttt tattctttct  
 799

tgatagaaac ctgcttacat ttaaccaagc ttctattatg ctttttcta acacagactt  
 859

tcttcaactgt ctttcattta aaaagaaatt aatgctctta agatatatat tttacgtagt  
 919

gctgacagga cccactcttt cattgaaagg tgatgaaaat caaataaaga atctcttcac  
 979

atgag  
 984

<210> 2  
 <211> 136  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Arg Thr Pro Gly Pro Leu Pro Val Leu Leu Leu Leu Leu Ala Gly  
 1 5 10 15

Ala Pro Ala Ala Arg Pro Thr Pro Pro Thr Cys Tyr Ser Arg Met Arg  
 20 25 30

Ala Leu Ser Gln Glu Ile Thr Arg Asp Phe Asn Leu Leu Gln Val Ser  
 35 40 45

Glu Pro Ser Glu Pro Cys Val Arg Tyr Leu Pro Arg Leu Tyr Leu Asp  
 50 55 60

Ile His Asn Tyr Cys Val Leu Asp Lys Leu Arg Asp Phe Val Ala Ser  
 65 70 75 80



Pro Pro Cys Trp Lys Val Ala Gln Val Asp Ser Leu Lys Asp Lys Ala  
 85 90 95

Arg Lys Leu Tyr Thr Ile Met Asn Ser Phe Cys Arg Arg Asp Leu Val  
 100 105 110

Phe Leu Leu Asp Asp Cys Asn Ala Leu Glu Tyr Pro Ile Pro Val Thr  
 115 120 125

Thr Val Leu Pro Asp Arg Gln Arg  
 130 135

<210> 3  
 <211> 613  
 <212> DNA  
 <213> Mus musculus  
  
 <220>  
 <221> CDS  
 <222> (31)..(447)  
 <223>

<400> 3  
 gagctgaccc agcagtaggc accaggcacc atg tca cca aaa aca cta cct ctg  
 54

Met Ser Pro Lys Thr Leu Pro Leu  
 1 5

ttg ctg ctg ctg gtg gtg gtg gtg ata gcc tgg cct ctg gca gta cag  
 102

Leu Leu Leu Leu Val Val Val Val Ile Ala Trp Pro Leu Ala Val Gln  
 10 15 20

tcc gcg ccc ccc acc tgc tac tct cgg atg ctg acc ctg agc cgt gag  
 150

Ser Ala Pro Pro Thr Cys Tyr Ser Arg Met Leu Thr Leu Ser Arg Glu  
 25 30 35 40

atc atg gca gac ttc cag agc ctg cag gct tca gag cct gag gat tcc  
 198

Ile Met Ala Asp Phe Gln Ser Leu Gln Ala Ser Glu Pro Glu Asp Ser  
 45 50 55

tgt gtg agg tac ttg ccc cgg ctt tac ctg gac atc cat aac tac tgt  
 246

Cys Val Arg Tyr Leu Pro Arg Leu Tyr Leu Asp Ile His Asn Tyr Cys  
 60 65 70

gtg ctg gcc aag ctg aga gac ttc gtg gct tct cct cag tgc tgg aag  
 294

Val Leu Ala Lys Leu Arg Asp Phe Val Ala Ser Pro Gln Cys Trp Lys  
 75 80 85

atg gcc gaa gtg gac act ctg aag gac aga gtg cgg aag ctg tat acc  
 342

Met Ala Glu Val Asp Thr Leu Lys Asp Arg Val Arg Lys Leu Tyr Thr  
 90 95 100

atc atg aac tcc ttc tgc agg cgg gac ttg gta ttc ctc tca gat gac  
 390

Ile Met Asn Ser Phe Cys Arg Arg Asp Leu Val Phe Leu Ser Asp Asp  
 105 110 115 120

tgc agt gcc tta gaa gac cca att ccc gag gcc acg ggt cct cca gac  
 438

Cys Ser Ala Leu Glu Asp Pro Ile Pro Glu Ala Thr Gly Pro Pro Asp  
 125 130 135

tgg cag agc taagcaggtg gaccagaaga acaaccaga ggtctgaagc  
 487

Trp Gln Ser

tgggccagtt gtccagagtt acacccccca cacacacacc caggtctact tttagtgcca  
 547

ctggttagacc tgccacatgt ctctagcttc tgaaacacca gtgaggggtcc tacctctgag  
 607

catgct  
 613

<210> 4  
 <211> 139  
 <212> PRT  
 <213> Mus musculus

<400> 4

Met Ser Pro Lys Thr Leu Pro Leu Leu Leu Leu Val Val Val Val  
 1 5 10 15

Ile Ala Trp Pro Leu Ala Val Gln Ser Ala Pro Pro Thr Cys Tyr Ser  
 20 25 30

Arg Met Leu Thr Leu Ser Arg Glu Ile Met Ala Asp Phe Gln Ser Leu  
 35 40 45

Gln Ala Ser Glu Pro Glu Asp Ser Cys Val Arg Tyr Leu Pro Arg Leu  
 50 55 60

Tyr Leu Asp Ile His Asn Tyr Cys Val Leu Ala Lys Leu Arg Asp Phe  
 65 70 75 80

Val Ala Ser Pro Gln Cys Trp Lys Met Ala Glu Val Asp Thr Leu Lys  
 85 90 95

Asp Arg Val Arg Lys Leu Tyr Thr Ile Met Asn Ser Phe Cys Arg Arg  
 100 105 110

Asp Leu Val Phe Leu Ser Asp Asp Cys Ser Ala Leu Glu Asp Pro Ile  
 115 120 125

Pro Glu Ala Thr Gly Pro Pro Asp Trp Gln Ser  
 130 135

<210> 5  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 5  
atgactgcaa tgccttggaa t  
21

<210> 6  
<211> 20  
<212> DNA  
<213> Homo sapiens

<400> 6  
tcccttagcg ctgacgatct  
20

<210> 7  
<211> 26  
<212> DNA  
<213> Homo sapiens

<400> 7  
cccaatccca gtgactacgg tcctgc  
26